252 related articles for article (PubMed ID: 25722226)
1. Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement.
Bartalena L; Macchia PE; Marcocci C; Salvi M; Vermiglio F
J Endocrinol Invest; 2015 Apr; 38(4):481-7. PubMed ID: 25722226
[No Abstract] [Full Text] [Related]
2. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
3. Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy.
Elbers L; Mourits M; Wiersinga W
Thyroid; 2011 Mar; 21(3):279-83. PubMed ID: 21190446
[TBL] [Abstract][Full Text] [Related]
4. Management of Graves' hyperthyroidism: present and future.
Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
[TBL] [Abstract][Full Text] [Related]
5. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
Krassas GE; Segni M; Wiersinga WM
Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
[TBL] [Abstract][Full Text] [Related]
6. Challenges and perspectives of selenium supplementation in Graves' disease and orbitopathy.
Bednarczuk T; Schomburg L
Hormones (Athens); 2020 Mar; 19(1):31-39. PubMed ID: 31721133
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Graves' hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy.
Tonacchera M; Chiovato L; Bartalena L; Cavaliere AF; Vitti P
J Endocrinol Invest; 2020 Feb; 43(2):257-265. PubMed ID: 31784912
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism.
Le Moli R; Malandrino P; Russo M; Lo Giudice F; Frasca F; Belfiore A; Vigneri R
Front Endocrinol (Lausanne); 2020; 11():367. PubMed ID: 32595602
[No Abstract] [Full Text] [Related]
9. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
Žarković M; Wiersinga W; Perros P; Bartalena L; Donati S; Okosieme O; Morris D; Fichter N; Lareida J; Daumerie C; Burlacu MC; Kahaly GJ; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
[TBL] [Abstract][Full Text] [Related]
10. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
[TBL] [Abstract][Full Text] [Related]
11. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study.
Marcocci C; Bruno-Bossio G; Manetti L; Tanda ML; Miccoli P; Iacconi P; Bartolomei MP; Nardi M; Pinchera A; Bartalena L
Clin Endocrinol (Oxf); 1999 Oct; 51(4):503-8. PubMed ID: 10583319
[TBL] [Abstract][Full Text] [Related]
12. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
[TBL] [Abstract][Full Text] [Related]
13. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
14. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.
García-Mayor RV; Álvarez-Vázquez P; Fluiters E; Valverde D; Andrade A
Endocrine; 2019 Feb; 63(2):316-322. PubMed ID: 30334140
[TBL] [Abstract][Full Text] [Related]
15. Effect of Addition of Thyroxine in the Treatment of Graves' Disease: A Systematic Review.
Li J; Bai L; Wei F; Wei M; Xiao Y; Yan W; Wei J
Front Endocrinol (Lausanne); 2020; 11():560157. PubMed ID: 33569041
[TBL] [Abstract][Full Text] [Related]
16. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.
Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Pinchera A
Thyroid; 1992; 2(2):171-8. PubMed ID: 1525588
[TBL] [Abstract][Full Text] [Related]
17. The Graves' disease, consensus of the French Society of Endocrinology.
Bartes B; Rodien P
Ann Endocrinol (Paris); 2018 Dec; 79(6):597-598. PubMed ID: 30340757
[No Abstract] [Full Text] [Related]
18. Selenium in the Treatment of Graves' Hyperthyroidism and Eye Disease.
Lanzolla G; Marinò M; Marcocci C
Front Endocrinol (Lausanne); 2020; 11():608428. PubMed ID: 33574798
[TBL] [Abstract][Full Text] [Related]
19. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.
Bartalena L
J Clin Endocrinol Metab; 2011 Mar; 96(3):592-9. PubMed ID: 21190983
[TBL] [Abstract][Full Text] [Related]
20. Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?
Bartalena L; Marcocci C; Lai A; Tanda ML
J Endocrinol Invest; 2008 Jun; 31(6):578-81. PubMed ID: 18591894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
